文献速递系统性红斑狼疮

早发性狼疮肾炎患者终末期肾病的风险:一项基于人群的队列研究

Risk of end-stage renal disease in patients with early-onset lupus nephritis: A population-based cohort study.
PubMed 文献 · Semin Arthritis Rheum · 2023-11-04

该回顾性研究利用2008年至2018年韩国全国医保数据库,比较早发性狼疮肾炎(EOLN)与迟发性狼疮肾炎(DOLN)患者进展至终末期肾病(ESRD)的风险。共纳入3779例系统性红斑狼疮(SLE)后发生狼疮肾炎的患者,其中EOLN组2281例(60%),DOLN组1489例(40%)。调整混杂因素后,EOLN与DOLN的ESRD风险相当(HR 1.10,95%CI 0.57-2.11);但在接受积极免疫抑制治疗的患者亚组中,DOLN组ESRD风险高于EOLN组(HR 2.6,95%CI 1.11-6.10)。

要点

  • EOLN与DOLN患者进展至ESRD的风险总体相当(HR 1.10,95%CI 0.57-2.11)。
  • 接受积极免疫抑制治疗者中,DOLN组ESRD风险高于EOLN组(HR 2.6,95%CI 1.11-6.10)。
  • EOLN组69例(3.0%)、DOLN组29例(1.9%)进展至ESRD。

核心结论

  • EOLN与DOLN患者进展至ESRD的风险总体相当。
  • 在接受积极免疫抑制治疗的患者中,与EOLN相比,DOLN与更高的ESRD进展风险相关。

研究设计与样本

  • 本研究为回顾性研究,使用2008年至2018年韩国全国医保数据库中的SLE新发病例。
  • 将狼疮肾炎患者分为两组:EOLN组(狼疮肾炎在SLE诊断后12个月内发生)和DOLN组(狼疮肾炎在SLE诊断12个月后发生)。
  • 从狼疮肾炎诊断日期随访至ESRD发生、死亡或末次随访。
  • 采用Cox比例风险模型预测进展至ESRD的风险比(HR),以死亡作为竞争风险。
  • 共识别3779例随访期间发生狼疮肾炎的SLE新发病例:EOLN组2281例(60%),DOLN组1489例(40%)。

主要发现

  • EOLN组69例(3.0%)和DOLN组29例(1.9%)进展至ESRD。
  • 调整混杂因素后,EOLN与DOLN的ESRD风险相当(HR 1.10,95%CI 0.57-2.11)。
  • 在接受积极免疫抑制治疗的患者亚组中(EOLN组670例,DOLN组179例),DOLN组ESRD风险高于EOLN组(HR 2.6,95%CI 1.11-6.10)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the risk of end-stage renal disease (ESRD) between patients with early-onset lupus nephritis (EOLN) and those with delayed-onset LN (DOLN). METHODS: This retrospective study of incident cases of systemic lupus erythematosus (SLE) used nationwide Korean claims databases and data from 2008 through 2018. We divided LN patients into two groups: the EOLN group (with LN onset within 12 months of SLE diagnoses) and the DOLN group (with LN onset later than 12 months after SLE diagnoses). Patients were observed from the date of LN diagnosis to the development of ESRD, death, or the last follow-up. Cox proportional hazards modeling was used to predict hazard ratios (HRs) for progression to ESRD with death as a competing risk. RESULTS: We identified 3779 incident SLE patients who developed LN during follow-up: 60 % (n = 2281) had EOLN, and 40 % (n = 1489) had DOLN. Sixty-nine patients with EOLN (3.0 %) and 29 patients with DOLN (1.9 %) progressed to ESRD. After adjusting for confounders, the ESRD risk associated with EOLN was comparable to the risk associated with DOLN (HR 1.10, 95 % confidence interval [CI] 0.57 to 2.11). In the subgroup of patients on aggressive immunosuppressive therapy (670 with EOLN and 179 with DOLN), the ESRD risk was higher in the DOLN group (HR 2.6, 95 % CI 1.11 to 6.10). CONCLUSION: The risk of ESRD was comparable between patients with EOLN and DOLN. However, among patients on aggressive immunosuppressive therapy, compared with EOLN, DOLN was associated with a higher risk of progression to ESRD.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Cho SK, Kim H, Han JY, et al. Risk of end-stage renal disease in patients with early-onset lupus nephritis: A population-based cohort study. Semin Arthritis Rheum. 2023. PMID: 37976812. doi:10.1016/j.semarthrit.2023.152308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。